Alpha Wealth Group founder Tom Fortino: Why you need to be engaged with your retirement plan

view original post

WASHINGTON (AP) — Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

The initial determination from the Centers for Medicare and Medicaid Services, or CMS, means that patients taking Biogen’s Aduhelm medication will have to be part of clinical trials to assess the drug’s effectiveness in slowing the progression of dementia. Medicare’s national coverage determination would become final this spring, following a public comment period and further evaluation by the agency.

Related Posts